Welcome to our dedicated page for Shineco news (Ticker: SISI), a resource for investors and traders seeking the latest updates and insights on Shineco stock.
Shineco Inc. develops and commercializes induced pluripotent stem cell technology platforms and has also described its business as providing innovative diagnostic medical products and related medical devices. Company news commonly covers biological cell assets, iPSC and mesenchymal stem cell initiatives, molecular detection kits, health products, and subsidiary activity across InfiniClone, Dong'ao Health and Fuzhou Meidashan Biotechnology.
Recurring developments include technology service contracts, cell-storage and blockchain-based cell-asset programs, strategic distribution and cooperation agreements, phospholipid extraction technology, Southeast Asian market expansion, reverse stock split actions, insider stock-purchase plans, equity financing, acquisitions, and Nasdaq listing-compliance matters.
Shineco, Inc. (NASDAQ: SISI) has launched its redesigned website to enhance user experience and inform stakeholders about its expansion into the life science industry. The modernized site features user-friendly navigation and easy access to corporate information, including management details and SEC filings. CEO Jennifer Zhan emphasized that the website revamp represents a significant step in showcasing the company's latest developments to shareholders and the investment community. This initiative reflects Shineco's commitment to improving brand awareness and market presence.
Shineco, Inc. (NASDAQ: SISI) announced a strategic cooperation agreement with Beijing Xihuan Psychological Consulting Co., Ltd. on February 21, 2022. The partnership aims to establish an industry-university-research-medical collaborative platform focusing on the psychological rehabilitation of tumor patients. Both companies will conduct research on mental health interventions, enhancing Shineco's tumor clinical treatment system. This initiative seeks to improve early diagnosis and treatment rates for tumor diseases by integrating psychological health into comprehensive care.
On February 16, 2022, Shineco, a producer of herbal medicines and biotech products, signed a strategic cooperation agreement with Beijing Jinshengyun Pharmaceutical Technology Co., Ltd. (JSY). The partnership aims to enhance R&D in innovative drugs and medical devices. JSY specializes in clinical trials and regulatory compliance, contributing expertise to the establishment of Shineco's pharmaceutical R&D center. This collaboration aligns with China's healthcare development goals, intending to seize market opportunities in the pharmaceutical industry.
Shineco (SISI) announced a partnership with Weifang Jianyi Medical Devices to jointly manufacture nuclear medicine imaging devices, including PET, PET-CT, and PET-MRI. This collaboration aims to produce up to 100 devices in 2022, each projected to cost between USD $1.10 million and $1.25 million. The partnership will leverage WJM's technological expertise, addressing the high demand for advanced imaging solutions in China, which is currently dominated by foreign firms like GE and Philips. The devices will be distributed to over 100 specialized hospitals for tumor diagnosis in China.
Shineco, Inc. (NASDAQ: SISI) has appointed Professor Qiyin Sun as Chief Medical Consultant to spearhead its tumor treatment research and innovation. Professor Sun, a prominent figure with over 30 years in medical R&D, has notable achievements in nuclear medicine and medical imaging. His expertise includes the development of radiodynamic therapy devices, certified by both the CFDA and FDA. Shineco's CEO, Jennifer Zhan, expressed confidence that Professor Sun's extensive experience will enhance the company’s R&D capabilities, aiming to improve diagnosis and treatment technologies for tumor patients.
Shineco, Inc. (NASDAQ: SISI) has announced its acquisition of a 51% stake in Xiang Peng You Kang (Beijing) Technology Co., Ltd. for approximately $5.6 million, paid with 700,551 shares at $8 each. This strategic move aims to accelerate Shineco's entry into the digital healthcare sector and enhance its services through XPYK's established medical platform. The deal is expected to close within 60 days, pending customary conditions. Shineco plans to leverage this acquisition to improve health management services and capture growth opportunities in China's expanding digital medical market.
Shineco, Inc. (NASDAQ: SISI) has entered into a securities purchase agreement to sell $2 million of its common stock at a price of $6.8546 per share to GHS Investments, LLC. The net proceeds will be utilized for acquiring biotech research companies, working capital, and general corporate purposes. This offering is conducted under an effective shelf registration statement with the SEC. Shineco is focused on producing Chinese herbal medicines and organic agricultural products, headquartered in Beijing.
Shineco, Inc. (NASDAQ: SISI) announced a potential acquisition of at least 51% equity interest in Xiang Peng You Kang (Beijing) Technology Co., Ltd. (XPYK) through non-binding framework agreements dated November 18, 2021. This strategic move aims to enhance Shineco's integrated medical and healthcare services, leveraging XPYK’s robust medical service platform. The acquisition is expected to facilitate digital transformation and broaden medical offerings across various demographics. The transaction's completion is contingent on due diligence and other customary closing conditions.
Shineco, Inc. (NASDAQ: SISI) announced a Memorandum of Understanding (MOU) to negotiate the acquisition of Dragon Pride Limited, a Hong Kong-based medical aesthetic service provider. This exclusive 90-day window aims to secure either 100% or at least 50% equity interest in Dragon Pride. With China's medical aesthetic market projected to exceed $75 billion by 2022, CEO Jennifer Zhan highlighted potential profitability from new centers. If successful, the acquisition could generate annual net profits of at least RMB 100 million.